Literature DB >> 15752121

Ultraviolet-free phototherapy.

Jean Krutmann1, Kathrin Medve-Koenigs, Thomas Ruzicka, Ulrich Ranft, Jan H Wilkens.   

Abstract

BACKGROUND: Ultraviolet (UV) radiation phototherapy has been used for decades in the management of common skin diseases. On the other hand, UV radiation is a complete carcinogen and as a consequence, UV phototherapy is usually not used for the long-term management of children and young adults and in combination with topical or systemic immunosuppressants.
PURPOSE: The therapeutic effectiveness of a new UV-free irradiation device in the treatment of patients with atopic hand and/or foot eczema was studied.
METHODS: In a single-blinded trial 10 patients with atopic hand and/or foot eczema were treated with a sham irradiation device and with the new developed UV-free irradiation device DermoDyne during the following 4 weeks. All irradiation's lasted 30 min per treatment three times weekly.
RESULTS: UV-free irradiation was found to induce a significant clinical improvement of atopic hand and foot eczema (P = 0.0001) in marked contrast to the sham-irradiation (P = 0.39).
CONCLUSION: Our studies demonstrate that visible light can be successfully used for the treatment of patients with atopic eczema.

Entities:  

Mesh:

Year:  2005        PMID: 15752121     DOI: 10.1111/j.1600-0781.2005.00141.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  3 in total

Review 1.  [Therapy of occupational skin diseases].

Authors:  S Soost; M Worm
Journal:  Hautarzt       Date:  2009-09       Impact factor: 0.751

2.  Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis.

Authors:  Detlef Becker; Elise Langer; Martin Seemann; Gunda Seemann; Isabel Fell; Joachim Saloga; Stephan Grabbe; Esther von Stebut
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

3.  A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma.

Authors:  Wang Lu-Qun; Li Hao; Li Xiang-Xin; Li Fang-Lin; Wang Ling-Ling; Chen Xue-Liang; Hou Ming
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.